Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Samuel Klempner

Samuel Klempner

Massachusetts General Hospital, Boston, MA

Biomarker testing in gastroesophageal cancer

Biomarker testing in gastroesophageal cancer

Samuel Klempner • 10 Jul 2024

Evaluating patient suitability for zolbetuximab in gastroesophageal cancer

Evaluating patient suitability for zolbetuximab in gastroesophageal cancer

Samuel Klempner • 10 Jul 2024

Management of nausea and vomiting in patients treated with zolbetuximab

Management of nausea and vomiting in patients treated with zolbetuximab

Samuel Klempner • 27 Jun 2024

Real-world biomarker testing and treatment patterns in advanced G/GEJ cancer

Real-world biomarker testing and treatment patterns in advanced G/GEJ cancer

Samuel Klempner • 27 Jun 2024

The best of gastric and gastroesophageal junction cancer at ASCO GI 2023

The best of gastric and gastroesophageal junction cancer at ASCO GI 2023

Samuel Klempner • 30 Jan 2023

DisTinGuish: DKN-01 with tislelizumab and chemotherapy in GC/GEJC

DisTinGuish: DKN-01 with tislelizumab and chemotherapy in GC/GEJC

Samuel Klempner • 30 Jan 2023

Developments in gastric and gastroesophageal cancer management

Developments in gastric and gastroesophageal cancer management

Samuel Klempner • 27 Jan 2023

Mechanisms of resistance to EFGR antibodies in mCRC

Mechanisms of resistance to EFGR antibodies in mCRC

Samuel Klempner • 26 Jan 2023